Education
About Us
Working with TipRanks
Follow Us
Silexion Therapeutics (SLXN)
NASDAQ:SLXN
SLXN Stock Chart & Stats
$2.21
-$0.10(-4.76%)
At close: 4:00 PM EST
$2.21
-$0.10(-4.76%)
Day’s Range― - ―
52-Week Range$2.18 - $63.45
Previous CloseN/A
Volume52.80K
Average Volume (3M)964.79K
Market Cap
$9.38M
Enterprise Value$7.25M
Total Cash (Recent Filing)$9.24M
Total Debt (Recent Filing)$485.00K
Price to Earnings (P/E)―
Beta-0.07
Next Earnings
Mar 24, 2026EPS Estimate
-1.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.88
Shares Outstanding3,126,642
10 Day Avg. Volume77,448
30 Day Avg. Volume964,790
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)-47.15
Price to Sales (P/S)0.00
P/FCF Ratio-22.34
Enterprise Value/Market Cap0.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.04K
Enterprise Value/Ebitda-0.97
Forecast
1Y Price Target
$12.00Price Target Upside442.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentSilexion plans to initiate a Phase 2/3 study for SIL-204, with meetings scheduled with regulators to discuss and finalize the study design, indicating progress towards clinical development.
Market PotentialKRAS mutations, which SIL-204 effectively targets, occur in high percentages of pancreatic, colorectal, non-small cell lung, and gastrointestinal cancers, indicating a broad market potential.
Regulatory SupportThe FDA awarding daraxonrasib a CNPV suggests the FDA is highly supportive of the KRAS targeting approach, thus when Silexion eventually files its IND in the U.S., there may be similar support in development.
Bears Say
Financial ConstraintsCash should be sufficient to initiate the Phase 2/3 trial, but additional capital will likely be required to complete the trial.
Stock Price TargetThe 12-month price target has been lowered to $12.00 from $24.00 due to the inclusion of additional shares from the capital raise.
Silexion Therapeutics News
SLXN FAQ
What was Silexion Therapeutics’s price range in the past 12 months?
Silexion Therapeutics lowest stock price was $2.18 and its highest was $63.45 in the past 12 months.
What is Silexion Therapeutics’s market cap?
Silexion Therapeutics’s market cap is $9.38M.
When is Silexion Therapeutics’s upcoming earnings report date?
Silexion Therapeutics’s upcoming earnings report date is Mar 24, 2026 which is in 120 days.
How were Silexion Therapeutics’s earnings last quarter?
Silexion Therapeutics released its earnings results on Nov 12, 2025. The company reported -$2.88 earnings per share for the quarter, beating the consensus estimate of -$3.4 by $0.52.
Is Silexion Therapeutics overvalued?
According to Wall Street analysts Silexion Therapeutics’s price is currently Undervalued.
Does Silexion Therapeutics pay dividends?
Silexion Therapeutics does not currently pay dividends.
What is Silexion Therapeutics’s EPS estimate?
Silexion Therapeutics’s EPS estimate is -1.07.
How many shares outstanding does Silexion Therapeutics have?
Silexion Therapeutics has 3,126,642 shares outstanding.
What happened to Silexion Therapeutics’s price movement after its last earnings report?
Silexion Therapeutics reported an EPS of -$2.88 in its last earnings report, beating expectations of -$3.4. Following the earnings report the stock price went up 3.559%.
Which hedge fund is a major shareholder of Silexion Therapeutics?
Currently, no hedge funds are holding shares in SLXN
Company Description
Silexion Therapeutics
Silexion Therapeutics (SLXN) is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapies for rare and complex diseases. Operating within the biotechnology and pharmaceuticals sector, Silexion Therapeutics specializes in creating targeted treatments that address unmet medical needs, leveraging advanced genetic and molecular technologies to develop its core products.
SLXN Stock 12 Month Forecast
Average Price Target
$12.00
▲(442.99% Upside)